Skip to main content
. Author manuscript; available in PMC: 2017 May 22.
Published in final edited form as: J Pain. 2016 Nov 21;18(3):233–246. doi: 10.1016/j.jpain.2016.10.020

Table 2.

Dimension 1: Core Diagnostic Criteria for Chemotherapy-Induced Peripheral Neuropathy

Criteria

  1. Onset of pain after exposure to a chemotherapeutic agent known to be neurotoxic

  2. Presence of painful symptoms in a symmetrical stocking and glove distribution beginning in lower extremities which may progress to the upper extremities, although finding in the feet and not in the hands is common

  3. Painful symptoms are accompanied by nonpainful symptoms (eg, “pins and needles” or numbness) in a similar distribution

  4. Clinical examination reveals sensory loss to 1 or more sensory modalities and/or evoked pain in a stocking and glove distribution, as reflected in at least 1 of the following:
    • Hypoesthesia: bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli, or
    • Hypoalgesia: bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli, or
    • Hyperalgesia: bilateral decrease in pain detection threshold to noxious heat or cold stimuli

  5. Magnitude of the sensory abnormalities is disproportionately greater than the magnitude of any motor abnormalities in the affected region (except in the case of neuropathy after vinca alkaloids)

  6. No other condition (eg, polyneuropathy of other origin) could plausibly account for painful symptoms